company background image
BLFS logo

BioLife Solutions NasdaqCM:BLFS Stock Report

Last Price

US$18.55

Market Cap

US$836.2m

7D

1.6%

1Y

-10.7%

Updated

28 Mar, 2024

Data

Company Financials +

BioLife Solutions, Inc.

NasdaqCM:BLFS Stock Report

Market Cap: US$836.2m

BLFS Stock Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

BLFS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BioLife Solutions, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioLife Solutions
Historical stock prices
Current Share PriceUS$18.55
52 Week HighUS$24.50
52 Week LowUS$8.92
Beta1.66
1 Month Change8.42%
3 Month Change14.15%
1 Year Change-10.73%
3 Year Change-49.44%
5 Year Change5.04%
Change since IPO-96.58%

Recent News & Updates

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Recent updates

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17
Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Aug 11
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

May 06
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Feb 22
Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Jan 10
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

BioLife: What The Future Holds

Oct 19

BioLife Solutions COO Roderick de Greef to retire

Oct 03

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Sep 27
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M

Aug 09

BioLife Solutions: Sell-Side Posture Overly Optimistic, Rate Neutral

Jul 29

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Jun 15
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

BioLife: Can This Company Successfully Turn Around?

Apr 18

Temporary Setbacks At BioLife

Mar 02

Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?

Jan 11
Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?

BioLife: Poised For Growth

Dec 22

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 81% Above Its Share Price

Nov 02
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 81% Above Its Share Price

Shareholder Returns

BLFSUS Life SciencesUS Market
7D1.6%-1.0%0.2%
1Y-10.7%3.7%28.1%

Return vs Industry: BLFS underperformed the US Life Sciences industry which returned 4.5% over the past year.

Return vs Market: BLFS underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is BLFS's price volatile compared to industry and market?
BLFS volatility
BLFS Average Weekly Movement6.4%
Life Sciences Industry Average Movement7.3%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BLFS has not had significant price volatility in the past 3 months.

Volatility Over Time: BLFS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987412Rod de Greefhttps://www.biolifesolutions.com

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

BioLife Solutions, Inc. Fundamentals Summary

How do BioLife Solutions's earnings and revenue compare to its market cap?
BLFS fundamental statistics
Market capUS$836.24m
Earnings (TTM)-US$66.43m
Revenue (TTM)US$143.27m

5.9x

P/S Ratio

-12.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLFS income statement (TTM)
RevenueUS$143.27m
Cost of RevenueUS$96.52m
Gross ProfitUS$46.75m
Other ExpensesUS$113.18m
Earnings-US$66.43m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.47
Gross Margin32.63%
Net Profit Margin-46.36%
Debt/Equity Ratio7.4%

How did BLFS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.